Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLV-154 in Subjects With Advanced Cancers
NCT06771219Phase 1Recruiting
- Sponsor
- Solve Therapeutics
- Start
- May 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SLV-154 in cancer and solid tumor, sponsored by Solve Therapeutics. Primary endpoints: Maximum Tolerated Dose at 18 months, Recommended Dosing Regimen at 18 months and 1 more. Started May 2025; status: recruiting.
02
Drugs
SLV-154
03
Conditions
cancersolid tumor
Beyond the preview
Go deeper on NCT06771219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06771219.